Antisoma: ATTRACT-1 phase III trial of ASA404 halted following interim analysis

30-Mar-2010 - United Kingdom
Antisoma plc announced that the planned interim analysis of data from the ATTRACT-1 phase III trial of ASA404 in previously untreated non-small cell lung cancer (NSCLC) has shown that continuation of the trial would be futile, as there is little or no prospect of demonstrating a survival benefit with ASA404 in this setting. The ATTRACT-1 trial will therefore be halted. No new or unexpected serious adverse effects of ASA404 have been identified by the trial's Data Monitoring Committee. Glyn Edwards, CEO of Antisoma, said: "We are disappointed by the outcome of the ATTRACT-1 study, especially given the very encouraging phase II data reported in the same setting. We had hoped that this trial would show that use of ASA404 could improve treatment for patients with newly diagnosed lung cancer. We are now focused on delivering phase III results for our other late-stage product, AS1413."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances